Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review
Abstract Background SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT) is a rare and highly aggressive malignancy characterized by early distant metastasis and a poor prognosis, with a median overall survival (OS) of only 4–7 months. Traditional therapies offer limited benefit, while eme...
Saved in:
| Main Authors: | Yu Gan, Qi Hu, Fangfang Hu, Shugui Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06284-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thoracic SMARCA4-deficient undifferentiated tumor
by: Yukina Izumi, et al.
Published: (2025-06-01) -
Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features
by: Ting Duan, et al.
Published: (2024-12-01) -
Metastatic SMARCA4-deficient undifferentiated tumor in the small mesentery: case report
by: Shuai Luo, et al.
Published: (2024-12-01) -
Updating the genomic and clinicopathologic features of thoracic SMARCA4-deficient undifferentiated tumor: a mini-series including a long-term survivor
by: Kenneth Ofori, et al.
Published: (2025-08-01) -
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
by: Yuanhang Wang, et al.
Published: (2024-12-01)